PTX
Prescient Therapeutics Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
5
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The firm is engaged in the development of personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 is a compound with the ability to block a cancer growth enzyme, geranylgeranyl transferase-1 (GGT-1). PTX-100 is in Phase Ib expansion cohort study in T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. PTX-200 is in Phase Ib/II trial in relapsed and refractory AML. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M is a platform for enhancing cell therapies by producing cells with superior phenotypes. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy.
📈 Performance
Price History
+649.79%
1M
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.08
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in PTX
5
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in PTX
800 days
PTX investor breakdown
💵 Income of investors
More than 200k
20%
150k - 200k
100k - 150k
50k - 100k
60%
Less than 50k
20%
👶 Age of investors
18 - 25
26 - 34
60%
35 - 90
40%
🙋 Legal gender of investors
Female
80%
Male
20%
Pearlers who invest in PTX also invest in...
FAIR.AX was created on 2017-11-27 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes Australian companies that have passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
📊 Share price
$18.55 AUD
NULL AUSTRALIA
NULL NEW ZEALAND
NULL ETHICAL
NULL THEMATIC
NULL SUSTAINABLE
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
📊 Share price
$104.08 AUD
NULL GLOBAL
NULL EX AUSTRALIA
NULL BETA
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
📊 Share price
$57.36 AUD
NULL GLOBAL
NULL SMART BETA
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
📊 Share price
$12.45 AUD
NULL GLOBAL
NULL SMART BETA
NULL ETHICAL
NULL EX AUSTRALIA
Fortescue Metals Group Ltd. engages in the development of iron ore deposits. The company is headquartered in Perth, Western Australia and currently employs 11,693 full-time employees. The firm is transitioning into a global green energy, metals and products company. Its segments include Metals and Fortescue Future Industries (FFI). The Metals segment is engaged in exploration, development, production, processing, sale and transportation of iron ore, and the exploration for other minerals. Fortescue Future Industries segment is involved in undertaking activities in the global development of green electricity, green hydrogen and green ammonia projects. Through its growth project Iron Bridge and its interest in the Belinga Iron Ore Project in Gabon, it is investing in the growth of its iron ore business. Its operations include three mining hubs in the Pilbara, Western Australia, which are connected to its five berth Herb Elliott Port and the Judith Street Harbour towage infrastructure in Port Hedland by approximately 760 kilometers of the heavy haul railway in the world.
📊 Share price
$19.87 AUD
NULL RESOURCES
Want more shares? Try these...
Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The company is also focused on developing therapies for a range of cancers, using CAR-T and targeted therapy approaches. The firm has a broad pipeline of cancer treatments, comprising CAR-T and targeted therapies, for cancers. Its product pipeline includes OmniCAR, PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. PTX-100 is a Phase Ib clinical candidate that block the cancer growth enzyme known as geranylgeranyl transferase-1. PTX-100 is in a pharmacokinetic basket study of hematological and solid malignancies, focusing on cancers with Ras and RhoA mutations. PTX-200 is in Phase Ib/IIa clinical candidate. PTX-200 is a novel PH domain inhibitor that inhibits an important tumor survival pathway known as Akt.